Sep 28 Earnings: Rite Aid - Way Oversold, Earnings Will Surprise
已更新
The company's share price has been under severe pressure since the deal with Walgreens 
WBA has fallen through and low pharmacy reimbursement rates.
Rite Aid's organic growth remains impressive, posting double digit sales growth in 2016. Earnings should get a boost from aggressive cost cutting measures.
I believe the company's share price is way oversold and earnings revisions should prove fruitful in the next 6 months.
I'm initiating the company with a $3.50 PT for the post-earnings move and upward of $4.00 heading into 2018.
WBA has fallen through and low pharmacy reimbursement rates. Rite Aid's organic growth remains impressive, posting double digit sales growth in 2016. Earnings should get a boost from aggressive cost cutting measures.
I believe the company's share price is way oversold and earnings revisions should prove fruitful in the next 6 months.
I'm initiating the company with a $3.50 PT for the post-earnings move and upward of $4.00 heading into 2018.
交易結束：達到停損點
Stop reached. Closed.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。